BC Extra | Jan 30, 2020
Company News

As Spinraza’s sales level off, Biogen presses ahead with aducanumab plans

Although Biogen’s earnings report suggests sales of SMA therapy Spinraza have plateaued, the company signaled its continued optimism that FDA will approve another potential blockbuster, its Alzheimer’s disease treatment aducanumab. Revenues from Spinraza nusinersen dipped...
BC Extra | Dec 3, 2019
Clinical News

Biogen plotting next steps in lupus after latest readout

As Biogen seeks to build its immunology franchise, it became the latest company to post encouraging data in lupus, with BIIB059 meeting the primary endpoints in a Phase II trial to treat both cutaneous lupus...
BC Extra | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
Items per page:
1 - 4 of 4